TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33423966
Drug: Chemotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy with capecitabine for 6 months
Study: 33423966
Drug: Chemotherapy and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy and radiochemotherapy
Study: 34730887
Drug: SHP block
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHP block with bupivacaine injection
Study: 34730887
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group with saline injection
Study: 34964679
Drug: Mobilization +
Normalized name: respiratory syncytial virus pre-fusion F protein, A, recombinant, stabilized / respiratory syncytial virus pre-fusion F protein, B, recombinant, stabilized Injection [Abrysvo]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mobilization + Physical Therapy
Study: 34881911
Drug: Dialectical behavior
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dialectical behavior therapy for PTSD (DBT-PTSD)
Study: 34928359
Drug: Cisplatin-based CCRT
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin-based CCRT (100 mg/m2 every 3 weeks for 3 cycles)
Study: 34928359
Drug: Nedaplatin-based CCRT
Normalized name: Nedaplatin
DrugBank: Nedaplatin (DB13145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nedaplatin-based CCRT (100 mg/m2 every 3 weeks for 3 cycles)
Study: 32618037
Drug: T. chebula
Approvals — FDA: no, EMA: no, PMDA: no
Description: T. chebula 250 mg
Study: 32618037
Drug: T. chebula
Approvals — FDA: no, EMA: no, PMDA: no
Description: T. chebula 500 mg
Study: 32857471
Drug: SPL 25
Approvals — FDA: no, EMA: no, PMDA: no
Description: SPL 25 mg/day plus topical benzoyl peroxide (BP) 2.5%
Study: 32857471
Drug: SPL 50
Normalized name: AVOBENZONE 3 g in 100 g / HOMOSALATE 10 g in 100 g / OCTISALATE 5 g in 100 g / OCTOCRYLENE 5 g in 100 g / OCTINOXATE 7.5 g in 100 g TOPICAL SPRAY [Bull Frog Mosquito Coast SPL 50 Pump]
Approvals — FDA: no, EMA: no, PMDA: no
Description: SPL 50 mg/day plus topical benzoyl peroxide (BP) 2.5%
Study: 32857471
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus topical benzoyl peroxide (BP) 2.5%
Study: 33749220
Drug: 1% sodium
Normalized name: Dextrose 5% and 0.11% Sodium Chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% sodium hexametaphosphate (SHMP) added to a 3% hydrogen peroxide bleaching gel applied for 6 hours per night for 2 weeks
Study: 33749220
Drug: 3% hydrogen
Normalized name: HYDROGEN PEROXIDE 30 mg in 1 mL TOPICAL LIQUID [3% Hydrogen Peroxide]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3% hydrogen peroxide bleaching gel (control group)
Study: 36050204
Drug: Spinal Cord
Normalized name: BOS TAURUS SPINAL CORD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spinal Cord Stimulation (SCS) therapy (40-Hz tonic SCS)
Study: 32406998
Drug: SYNERGY bioabsorbable
Normalized name: Senergy
Approvals — FDA: no, EMA: no, PMDA: no
Description: SYNERGY bioabsorbable polymer drug-eluting stent (BP-DES)
Study: 32414330
Drug: Durable polymer
Normalized name: dicresulene polymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Durable polymer drug-eluting stent (DP-DES)
Study: 32163564
Drug: OCP (ethinylestradiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: OCP (ethinylestradiol 30 μg/desogestrel 150 μg or ethinylestradiol 30 μg/drospirenone 3 mg) for 12-30 days with a 5-day washout period
Study: 34658781
Drug: Neuravena® (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neuravena® (800 mg)
Study: 32917359
Drug: Indacaterol/glycopyrronium 110/50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indacaterol/glycopyrronium 110/50 μg via Breezhaler® (IND/GLY)
Study: 32917359
Drug: Salbutamol/ipratropium 2.5/0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salbutamol/ipratropium 2.5/0.5 mg via air driven nebulization (SAL/IPR)
Study: 36062127
Drug: Juan Bi
Normalized name: bis-ethoxydiglycol succinate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Juan Bi Tang (JBT) - 3 g thrice daily for 4 weeks
Study: 36062127
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment for 4 weeks
Study: 35155599
Drug: Tolvaptan add-on
Normalized name: Tolvaptan
DrugBank: Tolvaptan (DB06212)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tolvaptan add-on therapy
Study: 36210496
Drug: Balance exercises
Normalized name: Rebalance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Balance exercises with mirror therapy
Study: 36210496
Drug: Balance exercises
Normalized name: Rebalance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Balance exercises without mirror therapy (control)
Study: 37167798
Drug: NPA-O2 (nasopharyngeal
Approvals — FDA: no, EMA: no, PMDA: no
Description: NPA-O2 (nasopharyngeal apnoeic oxygenation at 18 l/min)
Study: 32770667
Drug: Generic (test)
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Generic (test) formulation of 10‐mg alfuzosin extended‐release tablets
Study: 32770667
Drug: Branded (reference)
Normalized name: Eagle Brand Medicated Oil
DrugBank: Eucalyptus oil (DB11114)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Branded (reference) formulation of 10‐mg alfuzosin extended‐release tablets
Study: 33273475
Drug: Anti-hepatitis B
Normalized name: Anti-Hepatitis Be virus IgG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-hepatitis B core antibody (anti-HBc) testing
Study: 33273475
Drug: Antibodies against
Normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibodies against hepatitis C virus (anti-HCV) testing
Study: 32965623
Drug: MEL (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: MEL (3 mg) before exercise
Study: 32560181
Drug: Phe-10 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phe-10 g
Study: 32560181
Drug: Phe-5 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phe-5 g
Study: 36053605
Drug: Haemoglobin <50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haemoglobin <50 g/L
Study: 32800385
Drug: High-protein group
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-protein group (target energy 20 kcal/kg/day, protein 1.8 g/kg/day)
Study: 32800385
Drug: Medium-protein group
Normalized name: Medium-Chain Triglycerides
DrugBank: Medium-chain triglycerides (DB13959)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medium-protein group (target energy 20 kcal/kg/day, protein 0.9 g/kg/day)
Study: 34702773
Drug: Ceritinib administered
Normalized name: Ceritinib
DrugBank: Ceritinib (DB09063)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ceritinib administered for 10 days prior to tumor resection
Study: 35898448
Drug: Testosterone therapy
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone therapy (intramuscular testosterone cypionate 200 mg every 2 weeks for 18 months)
Study: 616761389
Drug: Daily activity
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily activity feedback (steps and active minutes) via an online program
Study: 32212002
Drug: Rituximab (RTX)
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab (RTX) treatment
Study: 34185225
Drug: Change scores
Normalized name: fecal microbiota spores, live Oral Capsule [Vowst]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Change scores and effect sizes across treatment response categories
Study: 34550930
Drug: Subfascial breast
Normalized name: chicken breast preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subfascial breast augmentation
Study: 35634285
Drug: SARS-CoV-2-mRNA vaccination
Normalized name: SARS-CoV-2 mRNA vaccine
DrugBank: SARS-CoV-2 mRNA vaccine (DB15855)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SARS-CoV-2-mRNA vaccination in IBD patients treated with TNF-α inhibitors
Study: 32592973
Drug: 80-kVp protocol
Normalized name: Olay Professional Acne Protocol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80-kVp protocol with 60 ml CM and ASIR-V
Study: 32592973
Drug: 80-kVp protocol
Normalized name: Olay Professional Acne Protocol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80-kVp protocol with 45 ml CM and ASIR-V
Study: 32592973
Drug: 120-kVp protocol
Normalized name: Olay Professional Acne Protocol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 120-kVp protocol with 60 ml CM and filtered back projection
Study: 36031855
Drug: Music therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Music therapy delivered using an MP3 player and headphones
Study: 33539062
Drug: Efinaconazole 10%
Normalized name: EFINACONAZOLE 10% SOLN,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Efinaconazole 10% topical solution applied once daily for 18-24 months
Study: 35245284
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of ITCs and ITJCs
Study: 32122397
Drug: Prophylactic swallowing
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic swallowing exercises (PSE) with face-to-face therapy by a speech and language pathologist
Study: 33729038
Drug: Cognitive behavior
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavior therapy (CBT) plus 36 sessions of group exercise
Study: 33711991
Drug: Pentosan polysulfate
Normalized name: Pentosan polysulfate
DrugBank: Pentosan polysulfate (DB00686)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pentosan polysulfate sodium (PPS) 2 mg/kg, subcutaneous, twice weekly for 6 weeks
Study: 34508594
Drug: Sarilumab monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sarilumab monotherapy (200 mg every 2 weeks)
Study: 33735463
Drug: Rocking therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rocking therapy for a minimum of 20 minutes daily
Study: 33735463
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group with same type of chair but without rocking therapy
Study: 39560745
Drug: Carbohydrate counting
Normalized name: pyrrolidone carboxylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbohydrate counting (CC)
Study: 32215726
Drug: Potato-based products
Approvals — FDA: no, EMA: no, PMDA: no
Description: Potato-based products (1.6 g kg-1)
Study: 32215726
Drug: Sport supplements
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sport supplements (1.6 g kg-1)
Study: 38806190
Drug: upadacitinib 15
Normalized name: upadacitinib 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: upadacitinib 15 mg once daily
Study: 35332058
Drug: upadacitinib 15
Normalized name: upadacitinib 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: upadacitinib 15 mg once daily (switched from placebo)
Study: 35341943
Drug: Ayurcov (three
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ayurcov (three doses on Day 1 as an adjuvant to standard of care)
Study: 32349059
Drug: 15 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg/kg loading dose intravenous infusion 30 minutes before surgery and again 3 hours later (Group C)
Study: 32349059
Drug: 15 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg/kg loading dose intravenous infusion 30 minutes before surgery (Group B)
Study: 32349059
Drug: 0.9% normal
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% normal saline solution without TXA (Group A)
Study: 32078815
Drug: All vaccine
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All vaccine regimens
Study: 34253077
Drug: Amplification of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amplification of Positivity Therapy (AMP) for alcohol use (AMP‐A) delivered in 11 individual sessions
Study: 33554268
Drug: Gentamicin ointment
Normalized name: gentamicin Ophthalmic Ointment
DrugBank: Gentamicin (DB00798)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gentamicin ointment
Study: 32540584
Drug: High-volume corticosteroid
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-volume corticosteroid injection (1 mL triamcinolone acetonide/40 mg, 9 mL anaesthetic agents)
Study: 32540584
Drug: Low-volume corticosteroid
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-volume corticosteroid injection (1 mL triamcinolone acetonide/40 mg)
Study: 35860380
Drug: Oral probiotics
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral probiotics (control group).
Study: 32698457
Drug: Pistachio group
Normalized name: Pistachio
DrugBank: Pistachio (DB10559)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pistachio group (1.5 oz/day or 42 g/day)
Study: 32597580
Drug: Phenazopyridine (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenazopyridine (200 mg, 2 tablets of 100 mg p.o., once)
Study: 32597580
Drug: Placebo (same
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (same administration scheme as phenazopyridine)
Study: 32329767
Drug: Intranasal Naloxone
Normalized name: NALOXONE RESCUE KIT INTRANASAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal Naloxone
Study: 32329767
Drug: Intramuscular Naloxone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular Naloxone
Study: 33526730
Drug: Spironolactone 25
Normalized name: spironolactone 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spironolactone 25 mg/day (group 1, n=30)
Study: 35413714
Drug: A. annua
Approvals — FDA: no, EMA: no, PMDA: no
Description: A. annua extracts sublingual immunotherapy (SLIT) with pharmacotherapy
Study: 32059728
Drug: Combined Aerobic
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined Aerobic and Resistance Exercise (CARE) program during chemotherapy
Study: 32206987
Drug: Xuezhitong (XZT)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xuezhitong (XZT) 2700 mg daily
Study: 32206987
Drug: Xuezhikang (XZK)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xuezhikang (XZK) 1200 mg daily
Study: 36965232
Drug: Brief Behavioral
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Brief Behavioral Therapy (BBT)
Study: 33302685
Drug: TNF-α antagonist
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: TNF-α antagonist etanercept 25 mg subcutaneous injection two times a week for two weeks
Study: 35476651
Drug: Standard care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard care (no nasal high-flow therapy or supplemental oxygen)
Study: 34225270
Drug: Cyclic steroid‐cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclic steroid‐cyclophosphamide regimen (modified Ponticelli protocol)
Study: 34225270
Drug: Rituximab (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rituximab (1 g × 2)
Study: 37855022
Drug: Overall treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall treatment (both doses)
Study: 34966017
Drug: Caudal epidural
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caudal epidural steroid injection (CESI)
Study: 35322972
Drug: Transforaminal epidural
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transforaminal epidural steroid injection (TFESI)
Study: 32594305
Drug: Rectal omeprazole
Normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rectal omeprazole (1 mg/kg)
Study: 32594305
Drug: Oral omeprazole
Normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral omeprazole (1 mg/kg)
Study: 32594305
Drug: Rectal omeprazole
Normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rectal omeprazole
Study: 32870520
Drug: Antidepressants prescription
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressants prescription
Study: 32198596
Drug: MSC therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: MSC therapy (Men‐MSCs)
Study: 34777570
Drug: Traditional paralysis
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional paralysis treatment
Study: 32444033
Drug: Lavender herbal
Normalized name: LAVENDER
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lavender herbal tea (2 g teabag, 2 times daily for 2 weeks)
Study: 32579066
Drug: Pyrazole based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pyrazole based sulfonamides; specific compounds include NMT106, NMT157, NMT187, NMT236; dosage and duration not specified.
Study: 34408049
Drug: No antiviral
Approvals — FDA: no, EMA: no, PMDA: no
Description: No antiviral treatment (Control)
Study: 33801767
Drug: High-flavanol cocoa
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-flavanol cocoa (150 mg)
Study: 33801767
Drug: Low-flavanol cocoa
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-flavanol cocoa (<4 mg (‐)‐epicatechin)
Study: 32163799
Drug: 200 ml
Normalized name: Bag Top-Fill, 1200 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 ml of grape juice
Study: 32163799
Drug: 75 g
Normalized name: Zosyn 3.375 GM Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 g maltodextrin
Study: 32163799
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no sugar administration)
Study: 34049672
Drug: 1 to
Normalized name: Cep-11981 tosylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 to 3 months of dual antiplatelet therapy (DAPT) followed by P2Y12 inhibitor monotherapy
Study: 32122921
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose cytarabine
Study: 32122921
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose cytarabine
Study: 36208303
Drug: Mindfulness-Based Intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mindfulness-Based Intervention (MB-SI) and Treatment as Usual (TAU)
Study: 34044838
Drug: Hypnosis group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypnosis group (standardized hypnotic message)
Study: 32167593
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy for former smokers
Study: 32167593
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy for current smokers
Study: 32167593
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy for former smokers with ≤20 pack-years
Study: 32167593
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy for all patients
Study: 32482611
Drug: 5% aluminium
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% aluminium zirconium tetrachlorohydrate antiperspirant solution (AZCH)
Study: 32197030
Drug: General anesthesia
Normalized name: Ethers for general anesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: General anesthesia (GA) (group G)
Study: 37183134
Drug: Negative pressure
Normalized name: DRESSING,NEGATIVE PRESSURE WOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Negative pressure wound therapy in stoma patients
Study: 32194443
Drug: Cariprazine (1.5-6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cariprazine (1.5-6 mg)
Study: 33142503
Drug: L-DNJ (0.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-DNJ (0.05 mg/g)
Study: 33142503
Drug: M-DNJ (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: M-DNJ (0.1 mg/g)
Study: 33142503
Drug: H-DNJ (0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: H-DNJ (0.15 mg/g)
Study: 36433591
Drug: Carbetocin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbetocin (100 μg intramuscularly)
Study: 35245895
Drug: All groups
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All groups (KT, KT-placebo, No-treatment control)
Study: 35613725
Drug: Eldecalcitol 0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eldecalcitol 0.75 μg per day (n=630)
Study: 34988058
Drug: Digital intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Digital intervention for medication adherence
Study: 34988058
Drug: Tailored intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tailored intervention content and reporting on medication taking
Study: 33278330
Drug: Single ascending
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single ascending dose (SAD) of vixotrigine
Study: 33278330
Drug: Multiple ascending
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple ascending dose (MAD) of vixotrigine (450 mg twice daily)
Study: 34684368
Drug: Caffeine (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (3 mg·kg−1)
Study: 32516494
Drug: Sequential text
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential text descriptions
Study: 2012036615
Drug: Olmesartan, 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olmesartan, 40 mg daily
Study: 32639293
Drug: Intranasal oxytocin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal oxytocin, n = 6
Study: 33405291
Drug: Restrictive transfusion
Normalized name: Pinus spp. wood destructive distillate
DrugBank: Pine tar (DB15840)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Restrictive transfusion strategy (triggered by hemoglobin ≤8 g/dL)
Study: 33405291
Drug: Liberal transfusion
Normalized name: dextromethorphan
DrugBank: Dextromethorphan (DB00514)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Liberal transfusion strategy (triggered by hemoglobin ≤10 g/dL)
Study: 34659110
Drug: Dulening metformin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dulening metformin SR tablets (n=446)
Study: 34659110
Drug: Glucophage metformin
Normalized name: metformin Oral Tablet [Glucophage]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucophage metformin tablets (n=440)
Study: 34708917
Drug: Difelikefalin (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Difelikefalin (5 and 15 mcg/kg)
Study: 33388858
Drug: Curcuminoids 500
Normalized name: METHYLCOBALAMIN 1 mg / LEVOMEFOLIC ACID 1 mg / CURCUMINOIDS 500 mg ORAL CAPSULE [Rheumate]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curcuminoids 500 mg/day
Study: 33388858
Drug: Curcuminoids 1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curcuminoids 1000 mg/day
Study: 34415561
Drug: Single oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose of 25 mg Omecamtiv mecarbil (OM)
Study: 34415561
Drug: Single oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose of 50 mg Omecamtiv mecarbil (OM)
Study: 34415561
Drug: Multiple oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple oral doses of 25 mg Omecamtiv mecarbil (OM)
Study: 34415561
Drug: Multiple oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple oral doses of 37.5 mg or 50 mg Omecamtiv mecarbil (OM)